Trial Outcomes & Findings for Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B (NCT NCT03672188)
NCT ID: NCT03672188
Last Updated: 2021-12-13
Results Overview
Number of Subjects with Adverse Events as assessed by CTCAE v5.0. In our planned analysis for this outcome measure, incidence is defined as the number of participants with treatment emergent AEs (TEAEs) in relation to the total number of participants in the cohort.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
82 participants
Primary outcome timeframe
Up to 364 days
Results posted on
2021-12-13
Participant Flow
Participant milestones
| Measure |
Part A: SAD VIR-2218 50 mg
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD VIR-2218 900 mg
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
6
|
6
|
6
|
8
|
6
|
6
|
12
|
3
|
6
|
6
|
3
|
3
|
3
|
6
|
2
|
|
Overall Study
Dosed
|
6
|
6
|
6
|
7
|
6
|
6
|
12
|
3
|
6
|
6
|
3
|
3
|
3
|
6
|
2
|
|
Overall Study
COMPLETED
|
6
|
6
|
5
|
5
|
6
|
6
|
12
|
3
|
6
|
6
|
3
|
3
|
2
|
6
|
2
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
Reasons for withdrawal
| Measure |
Part A: SAD VIR-2218 50 mg
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD VIR-2218 900 mg
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
Baseline characteristics by cohort
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=7 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=12 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=3 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
n=3 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
n=3 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
n=3 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
n=2 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Total
n=81 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=81 Participants
|
|
Age, Continuous
|
25 Years
STANDARD_DEVIATION 3 • n=6 Participants
|
23.3 Years
STANDARD_DEVIATION 4 • n=6 Participants
|
26.7 Years
STANDARD_DEVIATION 3.8 • n=6 Participants
|
24.3 Years
STANDARD_DEVIATION 3.7 • n=7 Participants
|
28.8 Years
STANDARD_DEVIATION 6.3 • n=6 Participants
|
32.5 Years
STANDARD_DEVIATION 9.5 • n=6 Participants
|
26.5 Years
STANDARD_DEVIATION 6.7 • n=12 Participants
|
40.3 Years
STANDARD_DEVIATION 9.1 • n=3 Participants
|
42.5 Years
STANDARD_DEVIATION 10.8 • n=6 Participants
|
45.2 Years
STANDARD_DEVIATION 5.5 • n=6 Participants
|
55 Years
STANDARD_DEVIATION 4 • n=3 Participants
|
35 Years
STANDARD_DEVIATION 9.8 • n=3 Participants
|
33.7 Years
STANDARD_DEVIATION 13.1 • n=3 Participants
|
44 Years
STANDARD_DEVIATION 7.2 • n=6 Participants
|
58.5 Years
STANDARD_DEVIATION 7.8 • n=2 Participants
|
33.4 Years
STANDARD_DEVIATION 11.5 • n=81 Participants
|
|
Sex: Female, Male
Female
|
6 Participants
n=6 Participants
|
4 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
7 Participants
n=7 Participants
|
3 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
5 Participants
n=12 Participants
|
1 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
3 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
1 Participants
n=2 Participants
|
44 Participants
n=81 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=6 Participants
|
2 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
7 Participants
n=12 Participants
|
2 Participants
n=3 Participants
|
5 Participants
n=6 Participants
|
5 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
1 Participants
n=2 Participants
|
37 Participants
n=81 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
2 Participants
n=81 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=6 Participants
|
6 Participants
n=6 Participants
|
6 Participants
n=6 Participants
|
7 Participants
n=7 Participants
|
6 Participants
n=6 Participants
|
5 Participants
n=6 Participants
|
11 Participants
n=12 Participants
|
3 Participants
n=3 Participants
|
6 Participants
n=6 Participants
|
6 Participants
n=6 Participants
|
3 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
6 Participants
n=6 Participants
|
2 Participants
n=2 Participants
|
79 Participants
n=81 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=12 Participants
|
3 Participants
n=3 Participants
|
5 Participants
n=6 Participants
|
5 Participants
n=6 Participants
|
3 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
6 Participants
n=6 Participants
|
2 Participants
n=2 Participants
|
39 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
2 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
6 Participants
n=81 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=6 Participants
|
2 Participants
n=6 Participants
|
5 Participants
n=6 Participants
|
5 Participants
n=7 Participants
|
3 Participants
n=6 Participants
|
3 Participants
n=6 Participants
|
8 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
29 Participants
n=81 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
0 Participants
n=81 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=6 Participants
|
2 Participants
n=6 Participants
|
1 Participants
n=12 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=2 Participants
|
7 Participants
n=81 Participants
|
|
Region of Enrollment
New Zealand
|
6 participants
n=6 Participants
|
6 participants
n=6 Participants
|
6 participants
n=6 Participants
|
7 participants
n=7 Participants
|
6 participants
n=6 Participants
|
6 participants
n=6 Participants
|
12 participants
n=12 Participants
|
0 participants
n=3 Participants
|
2 participants
n=6 Participants
|
1 participants
n=6 Participants
|
0 participants
n=3 Participants
|
1 participants
n=3 Participants
|
0 participants
n=3 Participants
|
0 participants
n=6 Participants
|
1 participants
n=2 Participants
|
54 participants
n=81 Participants
|
|
Region of Enrollment
South Korea
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=12 Participants
|
1 participants
n=3 Participants
|
1 participants
n=6 Participants
|
2 participants
n=6 Participants
|
2 participants
n=3 Participants
|
1 participants
n=3 Participants
|
0 participants
n=3 Participants
|
1 participants
n=6 Participants
|
0 participants
n=2 Participants
|
8 participants
n=81 Participants
|
|
Region of Enrollment
Hong Kong
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=12 Participants
|
1 participants
n=3 Participants
|
3 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=3 Participants
|
1 participants
n=3 Participants
|
1 participants
n=3 Participants
|
2 participants
n=6 Participants
|
0 participants
n=2 Participants
|
8 participants
n=81 Participants
|
|
Region of Enrollment
Australia
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=12 Participants
|
0 participants
n=3 Participants
|
0 participants
n=6 Participants
|
2 participants
n=6 Participants
|
0 participants
n=3 Participants
|
0 participants
n=3 Participants
|
2 participants
n=3 Participants
|
0 participants
n=6 Participants
|
0 participants
n=2 Participants
|
4 participants
n=81 Participants
|
|
Region of Enrollment
Thailand
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=7 Participants
|
0 participants
n=6 Participants
|
0 participants
n=6 Participants
|
0 participants
n=12 Participants
|
1 participants
n=3 Participants
|
0 participants
n=6 Participants
|
1 participants
n=6 Participants
|
1 participants
n=3 Participants
|
0 participants
n=3 Participants
|
0 participants
n=3 Participants
|
3 participants
n=6 Participants
|
1 participants
n=2 Participants
|
7 participants
n=81 Participants
|
|
Hepatitis B Surface Antigen Levels (IU/mL)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2372.227 IU/mL
STANDARD_DEVIATION 1168.940 • n=3 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
3872.625 IU/mL
STANDARD_DEVIATION 5678.292 • n=6 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
4009.863 IU/mL
STANDARD_DEVIATION 5239.703 • n=6 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
2374.423 IU/mL
STANDARD_DEVIATION 2078.034 • n=3 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
3488.037 IU/mL
STANDARD_DEVIATION 2454.215 • n=3 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
12640.983 IU/mL
STANDARD_DEVIATION 10495.983 • n=3 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
4819.127 IU/mL
STANDARD_DEVIATION 6348.594 • n=6 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
1886.045 IU/mL
STANDARD_DEVIATION 1223.655 • n=2 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
4456.52 IU/mL
STANDARD_DEVIATION 5657.74 • n=32 Participants • HBsAg levels would not be seen in Healthy subjects population, therefore 0 subjects were analyzed in corresponding dose levels.
|
|
Alanine Aminotransferase Levels
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
15.3 U/L
STANDARD_DEVIATION 4.6 • n=3 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
23.5 U/L
STANDARD_DEVIATION 14.9 • n=6 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
14.3 U/L
STANDARD_DEVIATION 5.0 • n=6 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
10.0 U/L
STANDARD_DEVIATION 4.0 • n=3 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
27.7 U/L
STANDARD_DEVIATION 18.6 • n=3 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
26.0 U/L
STANDARD_DEVIATION 17.7 • n=3 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
21.8 U/L
STANDARD_DEVIATION 17.6 • n=6 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
26.5 U/L
STANDARD_DEVIATION 10.6 • n=2 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
20.25 U/L
STANDARD_DEVIATION 13.08 • n=32 Participants • Alanine Aminotransferase Levels were not analyzed in Healthy subjects population.
|
PRIMARY outcome
Timeframe: Up to 364 daysPopulation: The Overall Number of Participants Analyzed is not consistent with numbers provided in the rows of the Participant Flow module because we enrolled and randomized 8 participants for the Part A 400 mg cohort, but only 7 of these participants were dosed and included for full analysis dataset. We have added a row for dosed participants in the Participant Flow module, to clarify this inconsistency and reflect the number of participants in the analysis dataset.
Number of Subjects with Adverse Events as assessed by CTCAE v5.0. In our planned analysis for this outcome measure, incidence is defined as the number of participants with treatment emergent AEs (TEAEs) in relation to the total number of participants in the cohort.
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=7 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=12 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=3 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
n=3 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
n=3 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
n=3 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
n=2 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Incidence of Adverse Events (AEs)
|
4 Participants
|
3 Participants
|
4 Participants
|
5 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
0 Participants
|
2 Participants
|
5 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Up to 336 daysPopulation: Number of participants analyzed is inclusive of clinically significant Vital Signs, ECGs, and Lab Findings. The Overall Number of Participants Analyzed is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Analysis Population Description in our First Primary Outcome Measure as well.
Number of participants with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=7 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=12 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=3 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
n=3 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
n=3 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
n=3 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
n=2 Participants
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
CTCAE v5.0 Lab Grade 0
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
CTCAE v5.0 Lab Grade 1
|
3 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
7 Participants
|
2 Participants
|
4 Participants
|
5 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
CTCAE v5.0 Lab Grade 2
|
1 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
CTCAE v5.0 Lab Grade 3
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
CTCAE v5.0 Lab Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
Clinically Significant Vital Signs
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Clinical Assessments Including But Not Limited to Laboratory Test Results
Clinically Significant ECG
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1; Part B/C: predose on Day 1 and at 1h, 2h, 4h, 8h, 24h postdose, Week 1, predose on Week 4 and at 1h, 2h, 4h, 8h, 24h postdose, and Week 5Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 and metabolite Maximum Concentration in Plasma
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=3 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=9 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Plasma Concentration (ng/mL)
VIR-2218 Cmax (Day 1)
|
155 ng/mL
Standard Deviation 65.3
|
355 ng/mL
Standard Deviation 117
|
711 ng/mL
Standard Deviation 207
|
2110 ng/mL
Standard Deviation 722
|
1830 ng/mL
Standard Deviation 615
|
5010 ng/mL
Standard Deviation 630
|
73.5 ng/mL
Standard Deviation NA
SD is not reported when n\<3. Not calculable; measurable in 2/3 subjects.
|
118 ng/mL
Standard Deviation 61.2
|
235 ng/mL
Standard Deviation 79.0
|
826 ng/mL
Standard Deviation 336
|
—
|
—
|
—
|
—
|
—
|
|
Maximum Plasma Concentration (ng/mL)
AS (N-1)3' VIR-2218 Cmax (Day 1)
|
NA ng/mL
Standard Deviation NA
Values were below the limit of quantification
|
40.5 ng/mL
Standard Deviation NA
SD is not reported when n\<3
|
62.4 ng/mL
Standard Deviation 17.6
|
259 ng/mL
Standard Deviation 114
|
177 ng/mL
Standard Deviation 99.2
|
514 ng/mL
Standard Deviation 106
|
NA ng/mL
Standard Deviation NA
Values were below the limit of quantification
|
NA ng/mL
Standard Deviation NA
Values were below the limit of quantification
|
NA ng/mL
Standard Deviation NA
Values were below the limit of quantification
|
66.1 ng/mL
Standard Deviation NA
SD is not reported when n\<3. Not calculable; measurable in 2/6 subjects.
|
—
|
—
|
—
|
—
|
—
|
|
Maximum Plasma Concentration (ng/mL)
VIR-2218 Cmax (Day 29)
|
—
|
—
|
—
|
—
|
—
|
—
|
51.8 ng/mL
Standard Deviation 21.1
|
115 ng/mL
Standard Deviation 38.2
|
256 ng/mL
Standard Deviation 167
|
807 ng/mL
Standard Deviation 374
|
—
|
—
|
—
|
—
|
—
|
|
Maximum Plasma Concentration (ng/mL)
AS (N-1)3' VIR-2218 Cmax (Day 29)
|
—
|
—
|
—
|
—
|
—
|
—
|
NA ng/mL
Standard Deviation NA
Values were below the limit of quantification
|
NA ng/mL
Standard Deviation NA
Values were below the limit of quantification
|
NA ng/mL
Standard Deviation NA
Mean not calculable if n=1
|
75.1 ng/mL
Standard Deviation 27.2
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1; Part B/C: predose on Day 1 and at 1h, 2h, 4h, 8h, 24h postdose, Week 1, predose on Week 4 and at 1h, 2h, 4h, 8h, 24h postdose, and Week 5Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 and metabolite time of Cmax in Plasma: Median (Inter-Quartile Range Q1-Q3)
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=3 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=9 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Time to Reach Maximum Plasma Concentration (h)
VIR-2218 Tmax Day 1
|
4.25 h
Interval 1.17 to 4.25
|
4.32 h
Interval 4.25 to 6.17
|
5.21 h
Interval 4.25 to 6.18
|
7.21 h
Interval 4.25 to 8.25
|
7.21 h
Interval 6.17 to 10.2
|
4.25 h
Interval 4.25 to 8.25
|
4.00 h
Interval 4.0 to 8.02
|
7.63 h
Interval 4.0 to 7.93
|
2.48 h
Interval 1.0 to 7.97
|
5.98 h
Interval 3.98 to 8.0
|
—
|
—
|
—
|
—
|
—
|
|
Time to Reach Maximum Plasma Concentration (h)
AS(N-1)3' VIR-2218 Tmax Day 1
|
NA h
Values were below the limit of quantification
|
6.17 h
Interval 4.25 to 6.17
|
6.17 h
Interval 4.25 to 6.18
|
9.21 h
Interval 4.25 to 10.2
|
10.2 h
Interval 8.25 to 10.2
|
8.25 h
Interval 4.25 to 10.2
|
NA h
Values were below the limit of quantification
|
NA h
Values were below the limit of quantification
|
NA h
Values were below the limit of quantification
|
8.00 h
Interval 7.97 to 8.0
|
—
|
—
|
—
|
—
|
—
|
|
Time to Reach Maximum Plasma Concentration (h)
VIR-2218 Tmax Day 29
|
—
|
—
|
—
|
—
|
—
|
—
|
3.95 h
Interval 0.92 to 4.0
|
4.00 h
Interval 4.0 to 7.98
|
8.00 h
Interval 4.0 to 8.0
|
3.99 h
Interval 2.0 to 8.0
|
—
|
—
|
—
|
—
|
—
|
|
Time to Reach Maximum Plasma Concentration (h)
AS (N-1)3' VIR-2218 Tmax Day 29
|
—
|
—
|
—
|
—
|
—
|
—
|
NA h
Values were below the limit of quantification
|
NA h
Values were below the limit of quantification
|
6.00 h
Interval 4.0 to 8.0
|
5.99 h
Interval 4.0 to 8.0
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1; Part B/C: predose on Day 1 and at 1h, 2h, 4h, 8h, 24h postdose, Week 1, predose on Week 4 and at 1h, 2h, 4h, 8h, 24h postdose, and Week 5Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 and metabolite Area under the curve from time 0 to last measurable Time
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=3 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=9 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
n=6 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (ng*h/mL)
VIR-2218 AUClast (Day 1)
|
1270 h*ng/mL
Standard Deviation 270
|
3740 h*ng/mL
Standard Deviation 1190
|
6630 h*ng/mL
Standard Deviation 1160
|
23500 h*ng/mL
Standard Deviation 2700
|
27900 h*ng/mL
Standard Deviation 7540
|
58800 h*ng/mL
Standard Deviation 9070
|
360 h*ng/mL
Standard Deviation 199
|
1000 h*ng/mL
Standard Deviation 285
|
2700 h*ng/mL
Standard Deviation 943
|
9570 h*ng/mL
Standard Deviation 2410
|
—
|
—
|
—
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (ng*h/mL)
AS(N-1) 3' VIR-2218 AUClast (Day 1)
|
NA h*ng/mL
Standard Deviation NA
Values were below the Limit of quantification
|
208 h*ng/mL
Standard Deviation 190
|
481 h*ng/mL
Standard Deviation 149
|
2530 h*ng/mL
Standard Deviation 613
|
2680 h*ng/mL
Standard Deviation 1460
|
6430 h*ng/mL
Standard Deviation 1500
|
NA h*ng/mL
Standard Deviation NA
Values were below the Limit of quantification
|
NA h*ng/mL
Standard Deviation NA
Values were below the Limit of quantification
|
NA h*ng/mL
Standard Deviation NA
Values were below the Limit of quantification
|
482 h*ng/mL
Standard Deviation 199
|
—
|
—
|
—
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (ng*h/mL)
VIR-2218 AUClast (Day 29)
|
—
|
—
|
—
|
—
|
—
|
—
|
339 h*ng/mL
Standard Deviation 171
|
910 h*ng/mL
Standard Deviation 326
|
2550 h*ng/mL
Standard Deviation 638
|
9580 h*ng/mL
Standard Deviation 3240
|
—
|
—
|
—
|
—
|
—
|
|
Area Under the Plasma Concentration Versus Time Curve (ng*h/mL)
AS(N-1) 3' VIR-2218AUClast (Day 29)
|
—
|
—
|
—
|
—
|
—
|
—
|
NA h*ng/mL
Standard Deviation NA
Values were below the Limit of quantification
|
NA h*ng/mL
Standard Deviation NA
Values were below the Limit of quantification
|
174 h*ng/mL
Standard Deviation NA
SD not calculated when n \< 3
|
393 h*ng/mL
Standard Deviation 230
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose and Week 1Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 Apparent Elimination Half-life t1/2 in Plasma: Median (Inter-Quartile Range Q1-Q3)
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=4 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apparent Terminal Elimination Half-life (h)
|
2.45 h
Interval 2.35 to 3.26
|
3.64 h
Interval 3.49 to 4.95
|
4.38 h
Interval 4.22 to 6.11
|
3.54 h
Interval 2.49 to 5.51
|
5.28 h
Interval 5.12 to 5.62
|
4.55 h
Interval 3.25 to 4.69
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose, and Week 1Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 CL/F Apparent plasma clearance
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=4 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apparent Plasma Clearance (L/h)
|
34.0 L/h
Standard Deviation 2.54
|
21.8 L/h
Standard Deviation 4.27
|
30.8 L/h
Standard Deviation 4.51
|
16.8 L/h
Standard Deviation 1.76
|
21.9 L/h
Standard Deviation 6.91
|
15.3 L/h
Standard Deviation 2.08
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Part A: predose on Day 1 and at 30 min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 24h, 48h postdose, and Week 1Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 VZ/F apparent volume of distribution
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=4 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apparent Volume of Distribution (L)
|
155 L
Standard Deviation 69.7
|
132 L
Standard Deviation 40.7
|
223 L
Standard Deviation 76.0
|
104 L
Standard Deviation 62.6
|
176 L
Standard Deviation 60.8
|
92.9 L
Standard Deviation 24.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pooled urine was collected at time interval D1 (0-4 hrs) (4-8 hrs) (8-12 hrs) and (12-24 hrs)Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 and metabolite: Fraction excreted in the urine from time 0 to 24 h. Pooled Urine PK samples was collected at pre-specified intervals in the single ascending dose study of VIR-2218. Therefore, the following PK parameter, fraction excreted in the urine ( %fe 0-24h ) was only calculated in healthy subjects who participated in Part A of the study. This parameter was not listed as a secondary endpoint for parts B/C in the submitted protocol, and as such was not reported in this secondary outcome measures.
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Urine %fe 0-24h
VIR-2218 fe 0-24
|
16.9 % excreted in the urine from time 0-24h
Standard Deviation 3.19
|
21.7 % excreted in the urine from time 0-24h
Standard Deviation 6.22
|
23.2 % excreted in the urine from time 0-24h
Standard Deviation 4.34
|
29.5 % excreted in the urine from time 0-24h
Standard Deviation 5.72
|
32.3 % excreted in the urine from time 0-24h
Standard Deviation 11.7
|
47.6 % excreted in the urine from time 0-24h
Standard Deviation 8.59
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Urine %fe 0-24h
AS(N-1)3' VIR-2218 fe 0-24
|
1.94 % excreted in the urine from time 0-24h
Standard Deviation 0.480
|
4.16 % excreted in the urine from time 0-24h
Standard Deviation 2.28
|
3.31 % excreted in the urine from time 0-24h
Standard Deviation 0.656
|
4.99 % excreted in the urine from time 0-24h
Standard Deviation 0.740
|
4.12 % excreted in the urine from time 0-24h
Standard Deviation 2.31
|
6.96 % excreted in the urine from time 0-24h
Standard Deviation 1.47
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pooled Urine was collected at time interval D1 (0-4 hrs) (4-8 hrs) (8-12 hrs) and (12-24 hrs)Population: The PK Analysis Set includes all randomized subjects who had at least 1 dose of VIR-2218 and 1 post-baseline PK parameter
VIR-2218 Apparent renal clearance from 0 to 24 h. Pooled Urine PK samples was collected at pre-specified intervals in the single ascending dose study of VIR-2218. Therefore, the following PK parameter, apparent renal clearance (CLR/F) was only calculated in healthy subjects who participated in Part A of the study. This parameter was not listed as a secondary endpoint for parts B/C in the submitted protocol, and as such was not reported in this secondary outcome measures.
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=4 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=5 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Apparent Renal Clearance (CLR/F)
|
5.87 L/h
Standard Deviation 0.728
|
5.22 L/h
Standard Deviation 1.27
|
7.00 L/h
Standard Deviation 0.659
|
5.13 L/h
Standard Deviation 0.850
|
7.22 L/h
Standard Deviation 1.480
|
7.47 L/h
Standard Deviation 1.340
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 112 daysMaximum reduction of serum HBsAg from Day 1 until Week 16.
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=6 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=2 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Reduction of Serum HBsAg From Baseline
|
-1.031 log10 IU/mL
Standard Deviation 0.574
|
-1.230 log10 IU/mL
Standard Deviation 0.702
|
-1.504 log10 IU/mL
Standard Deviation 0.540
|
-1.653 log10 IU/mL
Standard Deviation 0.154
|
-1.161 log10 IU/mL
Standard Deviation 0.350
|
-1.568 log10 IU/mL
Standard Deviation 0.636
|
-0.098 log10 IU/mL
Standard Deviation 0.047
|
-0.068 log10 IU/mL
Standard Deviation 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 336 daysSerum HBsAg loss is defined as quantitative HBsAg \< 0.05 IU/mL at two or more consecutive measurements
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=6 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=2 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Serum HBsAg Loss at Any Time Point
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 336 daysSerum HBsAg loss is defined as quantitative HBsAg \< 0.05 IU/mL at two or more consecutive measurements
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=6 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=2 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Sustained Serum HBsAg Loss for >/= 6 Months
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 336 daysAnti-HBs seroconversion is defined as anti-HBs positivity at two or more consecutive measurements
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=6 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
n=6 Participants
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
n=2 Participants
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With Anti-HBs Seroconversion at Any Timepoint
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 336 daysHBeAg loss is defined as quantitative HBeAg \< 0.11 IU/mL at two or more consecutive measurements. anti-HBe seroconversion is defined as anti-HBe positivity at two or more consecutive measurements
Outcome measures
| Measure |
Part A: SAD VIR-2218 50 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 100 mg
n=3 Participants
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 200 mg
n=2 Participants
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 400 mg
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2218 600 mg
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD VIR-2219 900 mg
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A: SAD Placebo
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B: MAD VIR-2218 20 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 50 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 100 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD VIR-2218 200 mg
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 50 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C: MAD VIR-2218 200 mg
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B: MAD Placebo
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C: MAD Placebo
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint
Number of Subjects with HBeAg Loss
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Subjects With HBeAg Loss and/or Anti-HBe Seroconversion at Any Timepoint
Number of Subjects with anti-HBe seroconversion
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Part A SAD: VIR-2218 50 mg
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Part A SAD: VIR-2218 100 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Part A SAD: VIR-2218 200 mg
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Part A SAD: VIR-2218 400 mg
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Part A SAD: VIR-2218 600 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Part A SAD: VIR-2218 900 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Part A SAD: Placebo
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Part B MAD: VIR-2218 20 mg
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Part B MAD: VIR-2218 50 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Part B MAD: VIR-2218 100 mg
Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths
Part B MAD: VIR-2218 200 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Part C MAD: VIR-2218 50 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Part C MAD: VIR-2218 200 mg
Serious events: 0 serious events
Other events: 2 other events
Deaths: 1 deaths
Part B MAD: Placebo
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Part C MAD: Placebo
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Part A SAD: VIR-2218 50 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 100 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 200 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 400 mg
n=7 participants at risk
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 600 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 900 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: Placebo
n=12 participants at risk
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B MAD: VIR-2218 20 mg
n=3 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: VIR-2218 50 mg
n=6 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: VIR-2218 100 mg
n=6 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: VIR-2218 200 mg
n=3 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C MAD: VIR-2218 50 mg
n=3 participants at risk
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C MAD: VIR-2218 200 mg
n=3 participants at risk
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: Placebo
n=6 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C MAD: Placebo
n=2 participants at risk
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Headache
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
Other adverse events
| Measure |
Part A SAD: VIR-2218 50 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 100 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 200 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 400 mg
n=7 participants at risk
Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 600 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: VIR-2218 900 mg
n=6 participants at risk
Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part A SAD: Placebo
n=12 participants at risk
Healthy subjects received a single dose of placebo administered SC
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part B MAD: VIR-2218 20 mg
n=3 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: VIR-2218 50 mg
n=6 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: VIR-2218 100 mg
n=6 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: VIR-2218 200 mg
n=3 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C MAD: VIR-2218 50 mg
n=3 participants at risk
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part C MAD: VIR-2218 200 mg
n=3 participants at risk
Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
VIR-2218: VIR-2218 given by subcutaneous injection
|
Part B MAD: Placebo
n=6 participants at risk
Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
Part C MAD: Placebo
n=2 participants at risk
Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
Placebo: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Palpitations
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Paraesthesia oral
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
8.3%
1/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Catheter site pain
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Fatigue
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
2/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Influenza like illness
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Injection site bruising
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
2/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Injection site discomfort
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
14.3%
1/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Injection site pain
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
14.3%
1/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Night sweats
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
General disorders
Pyrexia
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Infections and infestations
Gastroenteritis
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Infections and infestations
Influenza
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Infections and infestations
Upper respiratory tract infection
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
14.3%
1/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
2/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Infections and infestations
Viral infection
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
14.3%
1/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Infections and infestations
Viral upper respiratory tract
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Injury, poisoning and procedural complications
Eye contusion
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
14.3%
1/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Investigations
Cardiac murmur
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
50.0%
1/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Musculoskeletal and connective tissue disorders
Medial tibial stress syndrome
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
8.3%
1/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
2/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Nervous system disorders
Headache
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
50.0%
3/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
2/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
28.6%
2/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
2/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
2/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Renal and urinary disorders
Urinary tract infection
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
8.3%
1/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Respiratory, thoracic and mediastinal disorders
Dry throat
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
8.3%
1/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
33.3%
1/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
14.3%
1/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/7 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/12 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
16.7%
1/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/3 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/6 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
0.00%
0/2 • Up to 364 days after first dose with VIR-2218 or placebo
The Total Number of Participants at Risk - All Cause Mortality, Serious Adverse Events, and Other (Not Including Adverse Events) tables - is not consistent with numbers provided in the rows of the Participant Flow module. This inconsistency has been explained in the Baseline Analysis Population Description.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Investigators may discuss or publish results after: * the study results in their entirety have been publicly disclosed by or with the consent of the Sponsor OR study has been completed at all investigative sites for at least 2 years * provision of publication up to 60 days before planned submission to allow Sponsor to remove confidential information or identify Sponsor intellectual property Publication may be delayed as applicable, up to 120 days for Sponsor to file patent application(s)
- Publication restrictions are in place
Restriction type: OTHER